<--- Back to Details
First PageDocument Content
HIV/AIDS / Microbiology / Antibiotic-resistant bacteria / Cyclopropanes / Non-nucleoside reverse transcriptase inhibitors / Antiretroviral drug / Extensively drug-resistant tuberculosis / Tuberculosis treatment / AIDS / Tuberculosis / Medicine / Health
Date: 2010-09-29 05:18:06
HIV/AIDS
Microbiology
Antibiotic-resistant bacteria
Cyclopropanes
Non-nucleoside reverse transcriptase inhibitors
Antiretroviral drug
Extensively drug-resistant tuberculosis
Tuberculosis treatment
AIDS
Tuberculosis
Medicine
Health

Microsoft Word[removed]Adult ART Guidelines

Add to Reading List

Source URL: www.fidssa.co.za

Download Document from Source Website

File Size: 454,07 KB

Share Document on Facebook

Similar Documents

For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte

DocID: 1vkmw - View Document

PRESS RELEASE Adequate treatment essential to stop TB across Europe – new ECDC/WHO report Stockholm/Copenhagen, 19 MarchOverpatients are estimated to fall sick with tuberculosis (TB) every day across Euro

DocID: 1saSR - View Document

JOINT PRESS RELEASE New ECDC-WHO report: tuberculosis on the retreat in Europe. Concerns about drugresistant TB and treatment failure. Stockholm/Copenhagen, 19 March 2012

DocID: 1rHnT - View Document

Tuberculosis / Medicine / Clinical medicine / Health / Tuberculosis management / Tuberculosis diagnosis / DOTS / World Tuberculosis Day / TB Alert / Tuberculosis in India

15 | P a g e Multiple healthcare Seeking behaviors of new Smear positive pulmonary tuberculosis patients attending a diagnosis and treatment center of Bafoussam- Cameroon ABSTRACT FABRICE NEMBOT DJOUMA , ARMELLE VIVIAN

DocID: 1qzgC - View Document

Tuberculosis / Clinical medicine / Health / Medicine / Multi-drug-resistant tuberculosis / Bedaquiline / Tuberculosis management / Latent tuberculosis

Embargoed: 12 May – 1130 hrs CEST WORLD HEALTH ORGANIZATION RECOMMENDS SHORTENED NINE-MONTH TREATMENT REGIMEN FOR MDR-TB PATIENTS

DocID: 1q2l5 - View Document